Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AriBio Out-Licenses China Rights To Alzheimer’s Candidate in $770 Million Deal

publication date: Mar 25, 2024

South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million ($90 million upfront). The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs in China. AR1001 is an oral PDE5 inhibitor and originally a South Korean candidate for erectile dysfunction. In pre-clinical studies, AR1001 inhibited neuron apoptosis and restored synaptic plasticity, according to the company, and it has also shown the ability to reduce hyperphosphorylated tau proteins in a Phase II trial. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital